Program On Regulation, Therapeutics, And Law (PORTAL)
@portalresearch.org
Academic research center at Brigham and Women's Hospital & Harvard Medical School studying the clinical, economic, and legal aspects of medication use.
RETHINKING MEDICATIONS by Jerry Avorn - Out Now! https://rethinkmeds.info/
RETHINKING MEDICATIONS by Jerry Avorn - Out Now! https://rethinkmeds.info/
View his full testimony before the Health Subcommittee: waysandmeans.house.gov/event/health...
Read his written testimony: waysandmeans.house.gov/wp-content/u...
Read his written testimony: waysandmeans.house.gov/wp-content/u...
waysandmeans.house.gov
April 9, 2025 at 1:57 PM
View his full testimony before the Health Subcommittee: waysandmeans.house.gov/event/health...
Read his written testimony: waysandmeans.house.gov/wp-content/u...
Read his written testimony: waysandmeans.house.gov/wp-content/u...
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
April 9, 2025 at 1:57 PM
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
On protecting Medicaid - “Cutbacks planned for the Medicaid program will force states to severely limit their drug coverage, which will inevitably lead to patient deaths.”
April 9, 2025 at 1:57 PM
On protecting Medicaid - “Cutbacks planned for the Medicaid program will force states to severely limit their drug coverage, which will inevitably lead to patient deaths.”
They conclude: "If the FDA is going to continue to exercise maximal flexibility in considering when to approve highly promising drugs for patients in desperate need of treatment options, we believe policymakers should also protect patients from the economic implications of those decisions."
February 17, 2025 at 8:23 PM
They conclude: "If the FDA is going to continue to exercise maximal flexibility in considering when to approve highly promising drugs for patients in desperate need of treatment options, we believe policymakers should also protect patients from the economic implications of those decisions."